Results 281 to 290 of about 2,266,569 (385)

Immune Checkpoint Modulator [PDF]

, 2020
openaire   +1 more source

Precision Editing of NLRS Improves Effector Recognition for Enhanced Disease Resistance

Advanced Science, EarlyView.
Precision engineering of plant NLR immune receptors enables rational design of enhanced pathogen resistance through mismatched pairing, domain swapping, and targeted mutagenesis. These approaches achieve multi‐fold expansion in recognition breadth while minimizing autoimmunity risks and fitness penalties.
Vinit Kumar, Vishwa I. P. W. A. Kumara, Pradeepa C. G. Bandaranayake, Dong Yawen, Yang‐Yang Gao, Junfeng Liu, Ge‐Fei Hao, Xiu‐Fang Xin   +7 more
wiley   +1 more source

Research progress on immune checkpoint inhibitors in intrahepatic cholangiocarcinoma. [PDF]

Ann Med
Yin Z, Zhang L, Li J, Tan H, Ma B.
europepmc   +1 more source

Elemene Augments the Effects of Anti‐PD‐1 Immunotherapy on Hepatocellular Carcinoma by Regulating the miR‐130a‐5p/SPP/MHC‐I Axis

Advanced Science, EarlyView.
Elemene increases SPP expression by competitively binding with miR‐130a‐5p to suppress SPP mRNA degradation. This led to more antigen/MHC‐I complexes being expressed on the cell surface, which consequently facilitated the recognition and killing of HCC cells by CTLs and enhancing the antitumor immune efficacy of anti‐PD‐1.
Menglan Wang, Mengqing Sun, Heng Dong, Xiaoting Zhang, Jingbo Zhang, Zhengguo Zhang, Mengjie Ni, Lina Li, Yunxin Pei, Xiaoyu Chen, Qian Li, Fangtian Bu, Jiacheng Huang, Liangyu Jiang, Zhuting Fang, Xuliang Chen, Jianxiang Chen, Yiting Qiao, Tian Xie   +18 more
wiley   +1 more source

Hematological toxicity of immune checkpoint inhibitors: a pharmacovigilance study. [PDF]

BMC Cancer
Tan AJ, Lu JL, Li CX, Liu WY, Yan Y, Wang CH, Mo DC.   +6 more
europepmc   +1 more source

Supplementary Data from PRMT1 Inhibition Activates the Interferon Pathway to Potentiate Antitumor Immunity and Enhance Checkpoint Blockade Efficacy in Melanoma

Hongru Tao, Chen Jin, Liyuan Zhou, Zhenzhong Deng, Xiao Li, Wenzhen Dang, Shijie Fan, Bing Li, Fei Ye, Junyan Lu, Xiangqian Kong, Chuanpeng Liu, Cheng Luo, Yuanyuan Zhang   +13 more
openalex   +1 more source

Engineering Osteoimmune Responses with Functionalized Orthopedic Implants for Post‐Operative Osteosarcoma Treatment

Advanced Science, EarlyView.
Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong, Lingshuang Wang, Hui Zhang, Menghuan Li, Zhong Luo, Yan Hu, Chunyuan Cai   +6 more
wiley   +1 more source

Merkel cell carcinoma immunotherapy: key questions in the era of immune checkpoint blockade. [PDF]

J Immunother Cancer
Becker JC, Lodde G, Haist M, Ugurel S.
europepmc   +1 more source